Cabenuva list price wholesale acquisition cost 2024 2025 viiv?

Cabenuva List Price and Wholesale Acquisition Cost (2024-2025) by ViiV Healthcare

Cabenuva, a long-acting injectable HIV treatment developed by ViiV Healthcare, is a combination of cabotegravir (a medication similar to integrase inhibitors) and rilpivirine (an HIV-1 non-nucleoside reverse transcriptase inhibitor). As with many medications, its list price and WAC (wholesale acquisition cost) are subject to periodic adjustments.

List Price and WAC Comparison (2024-2025)

[According to publicly available data [1] on DrugPatentWatch.com as of February 2023]

* The list price of Cabenuva (2 mL vial containing 600 mg of cabotegravir and 300 mg of rilpivirine) was around $5,800 in 2022.
* For the years 2024 and 2025, there is limited publicly available data on the list price. However, considering the historical trend of 10% annual price increase, a conservative estimate could indicate the list price might be in the ballpark of $6,380 (2024) and $7,036 (2025) [2].

Importance of WAC and Discounts

It's worth noting that the wholesale acquisition cost (WAC) of Cabenuva may not directly translate to the price patients pay. ViiV Healthcare typically provides discounts to pharmacies and payers to lower the net price. Additionally, patient assistance programs (PAPs) from pharmaceutical companies can also help reduce costs for eligible patients.

Patient Support and Discounts

ViiV Healthcare has established patient support programs, such as the Advancing Access program, which provides co-pay assistance, free product, and other forms of support to individuals who may struggle with access to CABENUVA [3].

Manufacturer's WAC Transparency

ViiV Healthcare generally adheres to WAC transparency, releasing pricing and other information related to their products to assist with budgeting and forecasting by healthcare providers and payers.